Geode Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.75M Buy
997,128
+17,133
+2% +$42.6K ﹤0.01% 3090
2026
Q2
$2.28M Buy
979,995
+114,697
+13% +$243K ﹤0.01% 3162
2026
Q1
$1.88M Buy
865,298
+35,244
+4% +$87.5K ﹤0.01% 3149
2025
Q4
$1.49M Buy
830,054
+10,277
+1% +$21K ﹤0.01% 3256
2025
Q3
$1.82M Sell
819,777
-6,556
-0.8% -$10.7K ﹤0.01% 3205
2025
Q2
$1.22M Buy
+826,333
New +$1.69M ﹤0.01% 3271
2024
Q2
– Sell
-754,110
Closed -$950K – 4613
2024
Q1
$950K Buy
754,110
+29,535
+4% +$44.1K ﹤0.01% 3383
2023
Q4
$1.29M Buy
724,575
+24,364
+3% +$37.9K ﹤0.01% 3245
2023
Q3
$1.16M Buy
700,211
+147,840
+27% +$265K ﹤0.01% 3262
2023
Q2
$1.1M Buy
+552,371
New +$1.32M ﹤0.01% 3308

Other funds holding PLX

Geode Capital Management's PLX Position: Q3 2026 in Review

Geode Capital Management increased its Protalix BioTherapeutics (PLX) stake by 1.7% in Q3 2026, buying an estimated $42.6K and bringing the position to 997,128 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Geode Capital Management first reported a position in PLX in Q2 2023 and has held it in 10 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Geode Capital Management held 997,128 shares of Protalix BioTherapeutics worth $2.75M as of Q3 2026.
  • Geode Capital Management bought 17,133 Protalix BioTherapeutics shares in Q3 2026, an estimated $42.6K.
  • Protalix BioTherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3090 holding.
  • Geode Capital Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 10 quarters since.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.